Display options
Cite
Patel A, García-Closas M, Olshan AF, et al. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2021;82(1):25-35doi: 10.1158/0008-5472.CAN-21-1207.
Patel, A., García-Closas, M., Olshan, A. F., Perou, C. M., Troester, M. A., Love, M. I., & Bhattacharya, A. (2022). Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer research, 82(1), 25-35. https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel, Achal, et al. "Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer." Cancer research vol. 82,1 (2022): 25-35. doi: https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28. PMID: 34711612; PMCID: PMC8732329.
Copy Download .nbib Format: NLM
Share it on

Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28.

Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.

Cancer research

Achal Patel, Montserrat García-Closas, Andrew F Olshan, Charles M Perou, Melissa A Troester, Michael I Love, Arjun Bhattacharya

Affiliations

  1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
  2. Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
  3. Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
  4. Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
  5. Department of Genetics, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
  6. Department of Pathology and Laboratory Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
  7. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.
  8. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California. [email protected].
  9. Institute for Quantitative and Computational Biosciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, Carolina.

PMID: 34711612 PMCID: PMC8732329 DOI: 10.1158/0008-5472.CAN-21-1207

Abstract

Continuous risk of recurrence scores (CRS) based on tumor gene expression are vital prognostic tools for breast cancer. Studies have shown that Black women (BW) have higher CRS than White women (WW). Although systemic injustices contribute substantially to breast cancer disparities, evidence of biological and germline contributions is emerging. In this study, we investigated germline genetic associations with CRS and CRS disparity using approaches modeled after transcriptome-wide association studies (TWAS). In the Carolina Breast Cancer Study, using race-specific predictive models of tumor expression from germline genetics, we performed race-stratified (

©2021 The Authors; Published by the American Association for Cancer Research.

References

  1. Breast Cancer Res. 2017 Dec 11;19(1):131 - PubMed
  2. J Clin Oncol. 2009 Mar 10;27(8):1160-7 - PubMed
  3. BMC Med Genomics. 2015 Aug 22;8:54 - PubMed
  4. Nat Genet. 2015 Sep;47(9):1091-8 - PubMed
  5. JAMA. 2006 Jun 7;295(21):2492-502 - PubMed
  6. Ann Oncol. 2008 Sep;19(9):1566-72 - PubMed
  7. Am J Hum Genet. 2013 Aug 8;93(2):278-88 - PubMed
  8. Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):921-30 - PubMed
  9. JAMA Oncol. 2018 Apr 1;4(4):545-553 - PubMed
  10. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  11. Nat Genet. 2016 Mar;48(3):245-52 - PubMed
  12. Genome Biol. 2020 Feb 20;21(1):42 - PubMed
  13. J Natl Cancer Inst. 2020 Oct 1;112(10):1003-1012 - PubMed
  14. Genetics. 2012 Jun;191(2):607-19 - PubMed
  15. Integr Biol (Camb). 2015 Oct;7(10):1120-34 - PubMed
  16. PLoS Genet. 2020 May 5;16(5):e1008619 - PubMed
  17. J Stat Softw. 2010;33(1):1-22 - PubMed
  18. Cancer. 2014 Jul 15;120(14):2174-82 - PubMed
  19. Curr Biol. 2012 Feb 21;22(4):343-9 - PubMed
  20. Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135 - PubMed
  21. Oncogene. 2012 Feb 9;31(6):716-27 - PubMed
  22. Cell. 1989 Mar 10;56(5):829-38 - PubMed
  23. PLoS One. 2012;7(5):e37928 - PubMed
  24. Oncologist. 2013;18(9):986-93 - PubMed
  25. Arch Pathol Lab Med. 2016 Aug;140(8):815-24 - PubMed
  26. Nucleic Acids Res. 2001 Jan 1;29(1):308-11 - PubMed
  27. Brief Bioinform. 2021 May 20;22(3): - PubMed
  28. Nat Commun. 2019 Dec 11;10(1):5666 - PubMed
  29. Nat Genet. 2018 Jul;50(7):968-978 - PubMed
  30. Mol Med Rep. 2017 Dec;16(6):8477-8484 - PubMed
  31. Genome Biol. 2020 Aug 24;21(1):211 - PubMed
  32. PLoS Comput Biol. 2018 Feb 22;14(2):e1006026 - PubMed
  33. Genome Biol. 2014;15(12):550 - PubMed
  34. Clin Cancer Res. 2010 Dec 15;16(24):6100-10 - PubMed
  35. Genet Epidemiol. 2019 Sep;43(6):596-608 - PubMed
  36. Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1474-1482 - PubMed
  37. JAMA Oncol. 2017 Dec 1;3(12):1654-1662 - PubMed
  38. Breast Cancer Res. 2017 Nov 14;19(1):120 - PubMed
  39. Development. 2019 Apr 26;146(8): - PubMed
  40. Nat Commun. 2018 Oct 4;9(1):4079 - PubMed
  41. BMC Cancer. 2011 Aug 11;11:348 - PubMed
  42. PLoS Genet. 2009 Jun;5(6):e1000529 - PubMed
  43. Int J Cancer. 2019 Jan 15;144(2):263-272 - PubMed
  44. PLoS Genet. 2014 Apr 17;10(4):e1004234 - PubMed
  45. Genome Biol. 2017 Jan 27;18(1):19 - PubMed
  46. Proc Natl Acad Sci U S A. 2019 May 21;116(21):10447-10452 - PubMed
  47. Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 - PubMed
  48. PLoS Genet. 2020 Aug 14;16(8):e1008927 - PubMed
  49. Asian Pac J Cancer Prev. 2014;15(14):5539-44 - PubMed
  50. Am J Hum Genet. 2011 Jan 7;88(1):76-82 - PubMed
  51. Clin Cancer Res. 2017 Jun 1;23(11):2655-2664 - PubMed
  52. Genome Biol. 2010;11(10):R106 - PubMed
  53. Am J Hum Genet. 2005 May;76(5):887-93 - PubMed
  54. JAMA Oncol. 2020 Mar 1;6(3):385-392 - PubMed
  55. Int J Oncol. 2014 Jun;44(6):2025-33 - PubMed
  56. J Clin Oncol. 2013 Aug 1;31(22):2783-90 - PubMed
  57. Mol Cell Biol. 2000 Dec;20(24):9212-24 - PubMed
  58. Nat Genet. 2019 Jan;51(1):187-195 - PubMed
  59. Cancers (Basel). 2018 Aug 22;10(9): - PubMed
  60. Br J Cancer. 2019 Mar;120(6):647-657 - PubMed
  61. Biochem Biophys Res Commun. 2006 Dec 22;351(3):645-50 - PubMed
  62. Nature. 2015 Oct 1;526(7571):68-74 - PubMed
  63. Endocr Relat Cancer. 2011 Feb 23;18(2):207-19 - PubMed
  64. Nat Biotechnol. 2008 Mar;26(3):317-25 - PubMed
  65. J Natl Cancer Inst. 2021 Apr 6;113(4):390-399 - PubMed
  66. Oncol Lett. 2019 Feb;17(2):1732-1740 - PubMed
  67. Am J Hum Genet. 2020 Apr 2;106(4):496-512 - PubMed
  68. Am J Hum Genet. 2007 Sep;81(3):559-75 - PubMed
  69. Hum Pathol. 2009 Sep;40(9):1224-33 - PubMed
  70. PLoS Comput Biol. 2011 Oct;7(10):e1002240 - PubMed
  71. Biomark Cancer. 2010 Feb 11;2:1-15 - PubMed
  72. Breast Cancer Res Treat. 1995 Jul;35(1):51-60 - PubMed
  73. Breast Cancer Res. 2014 May 28;16(3):R53 - PubMed
  74. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13415-20 - PubMed
  75. J Natl Cancer Inst. 2018 Feb 1;110(2): - PubMed
  76. BMC Med Genomics. 2020 Aug 20;13(1):116 - PubMed
  77. Nat Methods. 2011 Dec 04;9(2):179-81 - PubMed
  78. NPJ Breast Cancer. 2020 Sep 10;6:44 - PubMed
  79. EBioMedicine. 2019 May;43:188-200 - PubMed
  80. Oncologist. 2013;18(2):123-33 - PubMed

Publication Types

Grant support